Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal impairment (creatinine clearance (CrCl) o30, 30-50, 51-80 and 480 ml min
Introduction
Renal impairment is a common complication in multiple myeloma (MM) patients during diagnosis. 1 Approximately 30% of patients have a serum creatinine X1.5 mg per 100 ml, [2] [3] [4] and approximately 1-13% require dialysis depending on the population and the type of treatment center. 3, [5] [6] [7] [8] [9] [10] Renal impairment in MM is primarily due to light-chain tubular cast nephropathy, 1, 7, 11 so-called 'myeloma kidney,' 12 while other precipitating/aggravating factors include dehydration, hypercalcemia and tumor lysis syndrome. 6, 11, 13, 14 Renal impairment, as evidenced by elevated serum creatinine or reduced creatinine clearance (CrCl), is associated with a decreased response to therapy 7 and an overall poor prognosis in terms of survival. 2, 3, 7, 9, [13] [14] [15] [16] [17] [18] This is likely due to the association of renal impairment with more advanced disease 2 and higher tumor burden, 14 the use of lower-dose therapy due to toxicity concerns and a high rate of early mortality 3, 7, 9 among these patients. Renal impairment is partially or fully reversible with therapy in 26-58% of patients, 3, 5, 7, 14, 19 and reversibility is more common in patients with only mild or moderate impairment. 3, 5, 7 Reversal of renal impairment is in turn associated with improved survival. 3, 7, 14 Nevertheless, renal impairment remains common throughout the course of disease.
Given the proportion of MM patients who experience renal impairment, the development of new treatment approaches for this subset of patients with poor prognosis is highly important. Moreover, prompt treatment and rapid disease control is key in this patient population, 20 along with early recovery of normal renal function; therefore, new therapeutic agents should have a rapid mechanism of action. In addition, to achieve optimal efficacy, it is important that these agents have a good safety profile and that the rate of dose reductions due to toxicity is not elevated in patients with renal impairment.
The proteasome inhibitor bortezomib (VELCADE, Millennium Pharmaceuticals Inc. Cambridge, MA, USA, and Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA) is approved in the United States 21 and European Union for the treatment of MM patients who have received at least one prior therapy, and in the United States for the treatment of mantle cell lymphoma patients who have received at least one prior therapy. 22 Bortezomib primarily undergoes hepatic oxidative metabolism, 22 and clearance has been shown to be independent of renal function. 23 Bortezomib alone and in combination has been shown to be active and well tolerated in both relapsed and newly diagnosed MM with varying degrees of renal impairment, including those requiring dialysis.
12,23-28
The international, phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study enrolled 669 patients with relapsed MM who had received 1-3 prior therapies and who had varying degrees of renal impairment. Patients were randomized to receive either single-agent bortezomib or highdose dexamethasone. 29 During the initial analysis of the study, bortezomib was shown to be significantly superior to dexamethasone in terms of time to progression (TTP), response rate (including complete response (CR) rate) and overall survival (OS). 29 The dexamethasone arm was consequently halted as per the recommendations of the independent data-monitoring committee, and a companion crossover study that had initially offered single-agent bortezomib only to dexamethasone patients with progressive disease, was opened to all dexamethasone patients. 29 In an updated analysis, with longer median followup, bortezomib was shown to provide a 6-month OS benefit compared with dexamethasone (median OS: 29.8 vs 23.7 months), despite 462% of dexamethasone patients having crossed over to receive single-agent bortezomib. 30 The aim of this exploratory subgroup analysis of the APEX study was to assess the efficacy and safety profiles of bortezomib in patients with different degrees of renal impairment and to compare these data with corresponding subgroups of patients in the dexamethasone arm. This study represents the first analysis of the efficacy of bortezomib in the setting of renal impairment in a large, unselected series of patients included in a randomized trial. Indeed, this is the first analysis of the impact of renal function on outcomes, including the impact on OS, conducted within a randomized trial.
Materials and methods
Full details of the APEX study have been published previously. 29 Briefly, patients were randomized (1:1) to receive bortezomib 31 every 3 weeks for 39 weeks and then every 6 weeks until disease progression. Adverse events (AEs) were graded using the National Cancer Institute Common Toxicity Criteria, version 2.0. Serious AEs (SAEs) were defined as any events that resulted in death, were life threatening, required hospitalization, resulted in persistent or substantial disability or had important medical consequences. 29 On-study deaths were defined as deaths occurring within 30 days after the last dose of study drug or deaths occurring after this time considered to be study-drug related.
Review boards at all participating institutions approved the study, and all patients provided written informed consent. The study was conducted according to the Declaration of Helsinki, the International Conference on Harmonisation and the Guidelines for Good Clinical Practice.
Analysis by degree of renal impairment
Patients in each arm were divided into four subgroups defined by their degree of renal impairment at baseline in terms of calculated CrCl, using the Cockcroft-Gault formula:
32 CrCl (ml min À1 ) ¼ ((140Àage at baseline in years) Â weight at baseline in kg)/(72 Â serum creatinine at baseline in mg per 100 ml) (for female patients, values are multiplied by 0.85). The Table 1 Baseline demographics and disease characteristics in patients treated with bortezomib or dexamethasone, by renal subgroups I  42  0  16  11  41  58  49  42  0  16  13  37  62  50  II  31  0  29  21  36  30  33  26  0  18  15  31  28  29  III  25  100  56  68  21  9  15  30  100  65  71  30  9  19 subgroups comprised patients with CrCl of o30, 30-50, 51-80 and 480 ml min À1 , corresponding to severe, moderate, mild and no renal impairment, respectively. Response rate (CR þ PR, European Group for Blood and Marrow Transplantation criteria) 31 was determined in response-evaluable patients, TTP and OS were evaluated on an intent-to-treat basis and incidences of AEs and SAEs were assessed in patients who received any amount of study drug (safety population). Analyses of response rate, TTP and safety were conducted using the initial APEX data set. 29 OS analysis was conducted using the updated APEX data set with extended follow-up (median 22 months). 30 As the number of patients with severe renal impairment in each treatment arm is small, statistical comparisons of TTP and OS were conducted and safety profile assessed, for subgroups of patients with CrCl of p50 ml min À1 (severe-to-moderate renal impairment) or 450 ml min À1 (no/mild renal impairment).
Statistical analysis
TTP and OS were assessed using Kaplan-Meier methods, and medians and 95% confidence intervals (CI) were calculated. A log-rank test was used for statistical comparisons of TTP and OS between the subgroups with severe-to-moderate and no/mild impairment within each treatment arm and between treatment arms for both subgroups.
Results
Of the 333 patients randomized to bortezomib in the APEX study, baseline CrCl data were available for 330 patients. CrCl of o30, 30-50, 51-80 and 480 ml min À1 was seen in 17 (5.2%), 45 (13.6%), 141 (42.7%) and 127 (38.5%) patients, respectively. In the bortezomib arm, median b 2 -microglobulin level at baseline was markedly higher in patients with CrCl of p50 vs 450 ml min
À1
, as would be expected, as was the proportion of patients with International Staging System 17 stage III disease. In addition, a lower proportion of bortezomib patients with CrCl of p50 ml min À1 had Karnofsky Performance Status X80%, compared with patients with CrCl of 450 ml min
. Similar observations were noted in the dexamethasone arm (Table 1) .
Efficacy
The response rate (CR þ PR) with bortezomib was similar across renal subgroups (Table 2 ). In patients with CrCl of p50 ml min À1 , the response rate was 40%, compared with 38% in patients with CrCl of 450 ml min
À1
. The median time to first response in patients was similarly rapid across renal subgroups and was the same in patients with severe-to-moderate and no/mild renal impairment (1.4 months).
TTP and OS with bortezomib appeared similar across renal subgroups, with overlapping CIs (Table 2) . Between bortezomib patients with CrCl of p50 and 450 ml min À1 , TTP and OS were not statistically different, although the data indicated a trend toward shorter OS in patients with severe-to-moderate renal impairment compared with patients with no/mild renal impairment (median TTP: 4.9 vs 6.2 months, P ¼ 0.62; median OS: 22.8 vs 30.0 months, P ¼ 0.07). Kaplan-Meier plots of TTP and OS in bortezomib patients with CrCl of p50 or 450 ml min À1 are shown in Figures 1 and 2 , respectively.
Bortezomib demonstrated greater efficacy compared with dexamethasone in all renal subgroups (Table 2) , reflecting the overall results of the APEX study. 29, 30 Response rate was Table 2 Response rate, time to progression and overall survival in patients treated with bortezomib and dexamethasone, by renal subgroups Response rate (CR+PR), n (%)
120 (38) 7 (47) 16 (37) 23 (40) 55 (40) 42 (36) 97 (38) 53 (17) 1 (10) 9 (17) 10 (16) 30 (25) 13 (11) 43 (18) CR, n (%)
4 (7) 11 (8) 5 (4) 16 (6) 2 (1)
100 (32) 7 (47) 12 (28) 19 (33) 44 (32) 37 (31) 81 (32) 51 (17) 1 (10) 8 (15) 9 (15) 30 (25) 12 (10) 42 (17) Median time to first response, months higher with bortezomib in patients with severe-to-moderate renal impairment (40 vs 16%) and in patients with no/mild renal impairment (38 vs 18%). Similarly, TTP was significantly longer with bortezomib compared with dexamethasone in patients with CrCl of p50 ml min À1 (median 4.9 vs 2.8 months; P ¼ 0.02) and in patients with CrCl of 450 ml min À1 (median 6.2 vs 3.5 months; Po0.0001; Figure 1 ). For OS, the data indicated a trend toward longer OS with bortezomib compared with dexamethasone in patients with both CrCl of p50 ml min À1 (median 22.8 vs 12.6 months; P ¼ 0.09) and CrCl of 450 ml min À1 (median 30.0 vs 25.3 months; P ¼ 0.09; Figure 2 ). Notably, there was a significant difference in OS between these renal subgroups for dexamethasone patients, with longer OS in patients with no/mild renal impairment (P ¼ 0.003).
Safety
Duration of bortezomib treatment was comparable across all renal subgroups. Patients with both severe-to-moderate and no/ mild renal impairment received a median of six cycles of bortezomib. The safety profile of bortezomib in the overall population was reflected in the renal subgroups with similar incidences of AEs, grade X3 AEs and SAEs between patients Figure 1 Time to progression in patients receiving bortezomib or dexamethasone with creatinine clearance of p50 ml min À1 (severe-to-moderate renal impairment) or 450 ml min À1 (no/mild renal impairment). P ¼ 0.62 for the comparison between bortezomib patients with CrCl p50 ml min À1 and bortezomib patients with CrCl 450 ml min À1 ; P ¼ 0.02 for the comparison between bortezomib patients with CrCl p50 ml min À1 and dexamethasone patients with CrCl p50 ml min
À1
; Po0.0001 for the comparison between bortezomib patients with CrCl 450 ml min À1 and dexamethasone patients with CrCl 450 ml min À1 . Figure 2 Overall survival in patients receiving bortezomib or dexamethasone with creatinine clearance of p50 ml min À1 (severe-to-moderate renal impairment) or 450 ml min À1 (no/mild renal impairment). P ¼ 0.07 for the comparison between bortezomib patients with CrCl p50 ml min
and bortezomib patients with CrCl 450 ml min
; P ¼ 0.09 for the comparison between bortezomib patients with CrCl p50 ml min À1 and dexamethasone patients with CrCl p50 ml min
; P ¼ 0.09 for the comparison between bortezomib patients with CrCl 450 ml min À1 and dexamethasone patients with CrCl 450 ml min with CrCl of p50 and 450 ml min À1 (Table 3 ). The overall incidence of peripheral neuropathy was significantly lower (Po0.05) in patients with CrCl of p50 vs 450 ml min À1 (13 vs 29%), but the incidence of grade X3 events was similar (7 vs 8%). A similar proportion of patients in each renal subgroup discontinued treatment due to an AE or had a dose reduction or interruption due to an AE (Table 3) . By contrast, in the dexamethasone arm, the rates of grade X3 AEs, SAEs and discontinuations due to AEs were significantly elevated (Po0.05) in patients with CrCl of p50 ml min À1 compared with those with CrCl of 450 ml min À1 (Table 4) , and the rate of dose reductions/interruptions also appeared higher. None of the on-study deaths that occurred in either treatment arm were related to renal causes.
Discussion
The results of this subgroup analysis of the phase 3 APEX study show that bortezomib is active and well tolerated in patients with relapsed MM with impaired renal function, including 17 patients with severe renal impairment (CrCl o30 ml min
À1
). The efficacy and safety of bortezomib do not appear to be substantially affected in patients with severe-to-moderate renal impairment in comparison to patients with no/mild renal impairment or the overall APEX population. Response rates and time to response were similar across the renal subgroups studied. Notably, time to first response to bortezomib was short in all subgroups; this is important as rapid disease control is the goal of treatment for patients with renal impairment. 20 TTP with bortezomib was similar between patients with severe-to-moderate and no/mild renal impairment. Likewise, OS curves were similar between these renal subgroups, although the data indicated a trend toward longer OS in patients with CrCl of 450 ml min À1 . This apparent difference in OS may reflect a more advanced disease in patients with CrCl of p50 ml min À1 , as evidenced in the differences seen in a number of disease characteristics at baseline (Table 1) .
Previously reported results from the APEX study demonstrated superior efficacy, in terms of higher overall response rate and CR rate, and longer median TTP and median OS, with bortezomib compared with dexamethasone. 29, 30 The results of the current subgroup analysis indicate that this advantage of efficacy is maintained regardless of renal impairment. Bortezomib treatment resulted in higher response rates than dexamethasone in all four renal subgroups. TTP was significantly longer with bortezomib compared with dexamethasone in the two broader subgroups of patients with severe-to-moderate or no/mild renal impairment.
Furthermore, the data indicated a trend toward longer OS with bortezomib vs dexamethasone in patients with CrCl of p50 or 450 ml min À1 . It is important to note that the negative impact of severe-to-moderate renal impairment on OS appeared Table 3 Most commonly reported adverse events of any grade (in X20% of total population) and of grade X3 (in X5% of total population), plus incidences of serious adverse events and discontinuations and dose reductions/interruptions due to adverse events, in patients treated with bortezomib, by renal subgroup
Creatinine clearance (ml min (26) 5 (29) 12 (27) 17 (28) 41 (29) 28 (22) 69 (26) Peripheral neuropathy NOS 85 (26) 1 (6) 7 (16) 8 (13) 42 (30) 35 (28) 77 (29)* Headache NOS 84 (26) 7 (41) 5 (11) 12 (20) 39 (28) 33 (26) 72 (27) Anorexia 74 (22) 5 (29) 13 (30) 18 (30) 34 (24) 22 (17) 56 (21) Cough 70 (21) 7 (41) 6 (14) 13 (21) 31 (22) 26 (20) 57 (21) Paraesthesia 67 (20) 1 (6) 10 (23) 11 (18) 35 (25) 21 (17) 56 (21) At least one grade X3 AE 246 (75) 14 (82) 30 (68) 44 (72) 102 (72) 100 (79) 202 (75) Thrombocytopenia 97 (29) 4 (24) 15 (34) 19 (31) 38 (27) 40 (31) 78 (29) Neutropenia 48 (15) 0 4 (9) 4 (7) 20 (14) 24 (19) 44 (16) Anemia NOS 32 (10) 2 (12) 6 (14) 8 (13) 17 (12) 7 (6) 24 (9) Peripheral neuropathy (high-level term) 26 (8) 0 4 (9) 4 (7) 11 (8) 11 (9) 22 (8) Diarrhea NOS 24 (7) 1 (6) 3 (7) 4 (7) 9 (6) 11 (9) 20 (7 Abbreviations: AE, Adverse event; NOS, not otherwise specified; SAE, seriously adverse event. *Po0.05 for the comparison between the incidence in patients with creatinine clearance p50 ml min À1 and in patients with creatinine clearance 450 ml min
, w 2 test.
more marked in the dexamethasone arm than in the bortezomib arm ( Figure 2 ), with the difference between dexamethasone patients with CrCl of p50 or 450 ml min À1 reaching statistical significance, something that was not seen among bortezomib patients. In fact, the OS curves suggest that patients with CrCl of p50 ml min À1 who received bortezomib had similar outcomes to patients with CrCl of 450 ml min À1 who received dexamethasone. Taken together, the data from this subgroup analysis suggest that treatment with bortezomib partially overcomes the poor prognosis conferred by renal impairment. However, comparisons of OS between the subgroups should be made with caution given the confounding factors of crossover to bortezomib from the dexamethasone arm and the availability of a number of active salvage regimens for subsequent therapy.
The results of this subgroup analysis also indicate that the presence of renal impairment does not result in marked changes in the safety profile of bortezomib in patients with MM and does not raise any new safety concerns. This is as expected, given the findings of a pharmacologic study of bortezomib in adult cancer patients with impaired renal function, which indicated that bortezomib clearance is independent of renal function. 23 The proportions of patients discontinuing bortezomib treatment due to AEs, or requiring dose modifications or interruptions due to AEs were similar in the subgroups of patients with CrCl of p50 or 450 ml min À1 . Consequently, the median duration of bortezomib therapy was similar across subgroups. These data show that the efficacy of bortezomib is not compromised by a specific need for reduction of dose in patients with renal impairment. By contrast, the effect of severe-to-moderate renal impairment on clinically significant toxicities appeared to be more marked in the dexamethasone arm, with patients with CrCl of p50 ml min À1 experiencing significantly elevated incidences of grade 3/4 AEs, SAEs and discontinuations due to AEs compared with those with CrCl of 450 ml min
. The findings of this analysis of the randomized APEX study regarding the efficacy and safety of bortezomib in patients with renal impairment are supported by other studies of bortezomib alone or in combination, in these patients. Bortezomib has been shown to be well tolerated in adult cancer patients regardless of CrCl in an NCI-sponsored pharmacological study. 23 On the basis of updated data from this study, the FDA recently approved revised labeling for bortezomib stating that dosage adjustments are not necessary for patients with renal insufficiency, including those requiring dialysis. 22 Renal function did not appear to significantly affect response rate, toxicity or extent of therapy in an analysis of two phase-2 studies of bortezomib in relapsed and/or refractory MM. 12 In other studies in renally impaired patients with relapsed MM, including patients requiring dialysis, bortezomib and bortezomib-based combinations have been shown to produce high response rates, with durable responses and CRs. [24] [25] [26] 28 Notably, Chanan-Khan et al. 25 reported a response rate of 75%, including 30% CR/near CR, with bortezomib-based combinations in a retrospective multicenter analysis of 24 patients with advanced renal failure requiring dialysis; furthermore, three patients became dialysis independent and one patient was spared dialysis.
Most of these studies involve small series of selected patients. However, the present analysis has been conducted using a very large series of unselected patients, enabling the evaluation of the efficacy of bortezomib in patients with varying degrees of renal impairment. Moreover, the design of the study enabled comparison of the efficacy of bortezomib with that of high-dose Table 4 Most commonly reported adverse events of any grade (in X15%* of total population) and of grade X3 (in X5% of total population), plus incidences of serious adverse events and discontinuations and dose reductions/interruptions due to adverse events, in patients treated with dexamethasone, by renal subgroup
Creatinine clearance (ml min (8) 11 (8) 21 (8) w Hyperglycemia NOS 28 (9) 0 5 (9) 5 (7) 11 (9) 12 (9) 23 (9) Thrombocytopenia 22 (7) 0 6 (11) 6 (9) 3 (2) 13 (10) 16 (6) Pneumonia NOS 21 (7) 2 (18) 4 (7) 6 (9) 8 (7) 7 (5) Abbreviations: AE, adverse event; NOS, not otherwise specified; SAE, seriously adverse event *Note: A lower cut-off incidence was used in this table compared with Table 3 to provide information on a similar number of the most common toxicities by creatinine clearance rate.
w Po.05 for the comparison between the incidence in patients with creatinine clearance p50 ml min À1 and in patients with creatinine clearance 450 ml min
dexamethasone, which has been considered as a gold standard for the treatment of MM patients with renal failure.
In conclusion, the present analysis represents to the best of our knowledge the first study on the prognostic influence of renal function within the setting of a randomized trial and demonstrates that bortezomib is active and well tolerated in patients with relapsed MM following 1-3 prior therapies and with varying degrees of renal impairment. The efficacy and safety of bortezomib were not substantially affected in patients with severe-to-moderate renal impairment compared with those with no/mild renal impairment, allowing similar dosage strategies. Therefore, on the basis of these results and those from other studies, plus the recent FDA-approved labeling change, bortezomib at the standard dose of 1.3 mg m À2 should be considered an appropriate treatment option for the sizeable proportion of patients with relapsed MM who have any degree of renal impairment.
